From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy

Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro

doi:10.1111/dth.14565

From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy

Dermatol Ther. 2021 Jan;34(1):e14565. doi: 10.1111/dth.14565. Epub 2020 Nov 30.

Authors

Paulo Ricardo Criado¹, Hélio Amante Miot², Thais Prota Hussein Pincelli³, Alexandre Todorovic Fabro⁴

Affiliations

¹ Department of Dermatology, Centro Universitário Saúde ABC, Santo André, São Paulo, Brazil.
² Department of Dermatology and Radiotherapy, Faculdade de Medicina da Unesp, Botucatu, São Paulo, Brazil.
³ Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA.
⁴ Department of Pathology and Forensic Medicine, Faculdade de Medicina de Ribeirão Preto da USP, São Paulo, Brazil.

Abstract

COVID-19 generates a complex systemic inflammatory response that can lead to death due to wide macrophage activation, endothelial damage, and coagulation in critically ill patients. SARS-CoV-2-induced lung injury due to inflammatory mediated thrombosis could be similar to the livedoid vasculopathy in the skin, supporting a translational comparison of these clinical settings. In this article, we discuss anticoagulation, suppression of inflammatory response, and hyperbaric oxygen therapy in the context of severe COVID-19 and livedoid vasculopathy.

Keywords: COVID-19; heparin; hyperbaric oxygenation; livedoid; thrombosis; vasculopathy.

Publication types

Review

MeSH terms

Anticoagulants / adverse effects
COVID-19* / complications
Heparin, Low-Molecular-Weight
Humans
Hyperbaric Oxygenation*
Inflammation / therapy
SARS-CoV-2
Skin Diseases / etiology*

Substances

Anticoagulants
Heparin, Low-Molecular-Weight